(1 - 9 von 28
)
German Biotech Leaders Identify Cross-Border Investment ...
www.bionity.com
Comparing business conditions for biotech companies in Germany and the United States, Thomas Christely added: "Germany has significantly lower operating costs." The panelists agreed that the cost advantages in Germany ...
SR Pharma PLC | Publication of Circular to Shareholders ...www.investegate.co.uk › articlePrint
www.investegate.co.uk
... Chairman Thomas Christely Melvyn Davies Finance Director Mulier Capital Bioscience Managers Limited Advisers to SR Pharma Advisers to ...
Investegate |SR Pharma PLC Announcements | SR Pharma PLC: Publication...
www.investegate.co.uk
Investegate announcements from SR Pharma PLC, Publication of Circular to Shareholders
Isis Pharma and atugen AG enter patent license agreementPharmabiz.com
test.pharmabiz.com
... offer target validation services, including the elucidation of disease pathways to partners," said Thomas Christely, atugen's Chief Operating Officer. › news
DigChip IC database
www.digchip.com
DigChip is a provider of integrated circuits documentation search engine, it is also distributor agent between buyers and distributors excess inventory stock.
Zum 1. Oktober beginnt Thomas Christély als CEO der ...MetrioPharm AG
www.metriopharm.com
› News › Pressemitteilu...
German Biotech Leaders Identify Cross-Border Investment Opportunities
www.bionity.com
Germany's biotechnology industry is actively seeking international investors to leverage opportunities in Europe's largest biotech market. With generous public...
Fitbug strives to get fitter, ships to sea for Anglesey and dark days...
www.proactiveinvestors.co.uk
Another turbulent last week, with the FTSE 100 opening at 5,060 points, rising all the way up to 5,300 mid week and closing out at 5,130.
miRagen and Silence Evaluate Liver-Targeting Delivery Platform for...
www.genengnews.com
Companies will formulate miRagen miRNAs using Silence’s DBTC technology.
sortiert nach Relevanz / Datum